United Therapeutics Corporation (UTHR - Analyst Report) is set to report first-quarter ... is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1, 2 or 3 for this to happen.
ZACKS · 4/27/2015
What: Shares of United Therapeutics (NASDAQ: UTHR ) , a biopharmaceutical company that develops ... make up for the eventual loss of exclusivity on Remodulin, then chasing the stock higher after today may not be the best idea. United Therapeutics may ...
The Motley Fool · BySean Williams · 8/30/2014
As a part of our small-cap strategy, we analyze the equity portfolios of over 700 hedge funds, because we believe that hedge fund managers are still some of the best stock pickers, even though in the last couple of years many of them have not delivered any ...
INSIDER MONKEY · 4/16/2015
Within this sub-industry, one stock that has been a strong performer this Fall is United Therapeutics Corp (UTHR). Ever since August 29th when a US District Court judge made a favorable ruling on patents over the Remodulin drug, UTHR has been on fire.
Stockhouse · 10/21/2014
UTHR stock price is reasonably priced at 18.5 times current EPS, but the company reported two quarterly deficits during the past two years. The deficits were caused by extensive share-based compensation to executives and employees. Earnings are …
Cabot Investing Advice · 3/23/2015
United Therapeutics Corporation (UTHR) experienced unusually high volume on Apr. 27, as the stock lost 7.75% to a closing price of $172.22. The stock saw 1.27 million shares trade hands over the course of the day on 14,202 trades. Given that the …
Equities · 4/27/2015
Active traders and day traders have many stocks to choose from this Monday morning. We are tracking news and moves in shares of BioSante Pharmaceuticals (NASDAQ: BPAX), unOpta, Inc. (NASDAQ: STKL), and United Therapeutics Corporation …
24/7 Wall ST · 6/6/2011
Releasing their earnings report Tuesday, United Therapeutics Corporation (UTHR) closed Tuesday at $155.16 ... Earnings, adjusted for stock option expense and non-recurring costs, were $3.21 per share. The results topped Wall Street expectations. · 2/25/2015
United Therapeutics Inc. (UTHR) stock rallied 28.5% yesterday on news that the biopharmaceutical company has received a favorable court ruling in a patent fight with Novartis AG (NVS). In 2011, Sandoz International, Novartis’ subsidiary, announced plans ... · 8/30/2014
UTHR) and TNI BioTech, Inc (OTCMKTS: TNIB): Are Concerns About Drug Prices Overblown? Credit Suisse analyst Ravi Mehrotra believes a rally in large-cap biotech stocks can be resurrected in part because concerns about drug prices might be overblown ...
Smallcap Network · ByJohn Udovich · 5/16/2014